Insider Trade: Scott Holmes Sold 2,830 Shares of Keryx Biopharmaceuticals, Inc. (KERX); TRAVELSKY TECH LTD H (TSYHF) Shorts Increased By 0.7%

The Chief Financial Officer of Keryx Biopharmaceuticals Inc, Scott Holmes is in the stock market news today. We discovered in a report filled by Scott Holmes and submitted to the Security and Exchange Commission on January 31, 2018, he sold 2,830 shares from the New York-based company worth near $13,612 US Dollars. The mentioned shares average price was $4.8. Scott Holmes right now owns 136,870 shares which make up roughly 0.11% of the New York-based company’s market cap (total dollar market value of all company’s outstanding shares).

TRAVELSKY TECH LTD H (OTCMKTS:TSYHF) had an increase of 0.7% in short interest. TSYHF’s SI was 2.45 million shares in February as released by FINRA. Its up 0.7% from 2.43 million shares previously. With 1,000 avg volume, 2448 days are for TRAVELSKY TECH LTD H (OTCMKTS:TSYHF)’s short sellers to cover TSYHF’s short positions. It closed at $3.19 lastly. It is down 0.00% since February 1, 2017 and is . It has underperformed by 16.70% the S&P500.

Among 15 analysts covering Keryx Biopharmaceuticals (NASDAQ:KERX), 6 have Buy rating, 2 Sell and 7 Hold. Therefore 40% are positive. Keryx Biopharmaceuticals has $18 highest and $1.80 lowest target. $8.79’s average target is 89.85% above currents $4.63 stock price. Keryx Biopharmaceuticals had 36 analyst reports since July 23, 2015 according to SRatingsIntel. Raymond James initiated the stock with “Market Perform” rating in Wednesday, September 9 report. The firm earned “Buy” rating on Wednesday, November 9 by Maxim Group. Zacks upgraded the shares of KERX in report on Friday, August 28 to “Sell” rating. The firm has “Outperform” rating given on Tuesday, August 2 by Raymond James. The firm has “Mkt Perform” rating given on Tuesday, August 11 by FBR Capital. The firm has “Equal-Weight” rating given on Monday, October 5 by Morgan Stanley. The rating was upgraded by Citigroup to “Neutral” on Wednesday, January 11. Maxim Group maintained the stock with “Buy” rating in Tuesday, March 29 report. As per Thursday, August 13, the company rating was initiated by Morgan Stanley. Maxim Group maintained Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) rating on Friday, July 8. Maxim Group has “Buy” rating and $9 target.

Keryx Biopharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on providing medicines for patients with renal disease in the United States. The company has market cap of $552.00 million. It markets its lead product Auryxia , an orally available, absorbable, iron medicine for the control of serum phosphorus levels in patients with chronic kidney disease on dialysis. It currently has negative earnings. The firm has licensing and collaboration agreements with Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd. for the development and commercialization of Auryxia in Japan.

Analysts await Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) to report earnings on March, 7. They expect $-0.19 EPS, up 40.63% or $0.13 from last year’s $-0.32 per share. After $-0.20 actual EPS reported by Keryx Biopharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -5.00% EPS growth.

The stock decreased 1.91% or $0.09 during the last trading session, reaching $4.63. About 834,756 shares traded. Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) has risen 13.56% since February 1, 2017 and is uptrending. It has underperformed by 3.14% the S&P500.

Investors sentiment decreased to 1.5 in Q3 2017. Its down 0.47, from 1.97 in 2017Q2. It is negative, as 12 investors sold Keryx Biopharmaceuticals, Inc. shares while 26 reduced holdings. 14 funds opened positions while 43 raised stakes. 75.60 million shares or 1.12% less from 76.46 million shares in 2017Q2 were reported. Sei holds 340 shares. Usca Ria Ltd Liability Company accumulated 20,800 shares. 20,473 are owned by Virtu Fin Limited Liability Corp. Pub Employees Retirement Association Of Colorado reported 32,231 shares. Deltec Asset Ltd Liability Com invested in 0.03% or 20,000 shares. Prudential Financial reported 10,385 shares stake. Fmr Limited holds 0% of its portfolio in Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) for 2.24M shares. Clearbridge Invs Lc stated it has 8,635 shares. Wolverine Asset Mgmt Ltd reported 16,594 shares. Northern Tru holds 0% or 1.13M shares. Aperio Gp Lc holds 13,226 shares. Clearbridge Ltd Company owns 1.61M shares for 0.25% of their portfolio. Baupost Group Ltd Company Ma owns 25.79M shares for 2.28% of their portfolio. Rhumbline Advisers accumulated 101,041 shares. Prelude Capital Management Ltd Llc reported 1,191 shares.